Sai Parenterals IPO Underwhelming: Subscribed Just 0.41 Times

As of Wednesday, March 25, 2026, the Initial Public Offering (IPO) of Sai Parenterals has garnered bids for 30.82 lakh shares, falling short of the 75.22 lakh shares available, resulting in a subscription rate of 0.41 times. The bidding period for this IPO commenced on March 24, 2026, and is scheduled to conclude on March 27, 2026. The shares are offered within a price range of Rs 372 to Rs 392 per equity share.

The company is seeking to raise Rs 285 crore through a fresh issue of shares. These funds are earmarked for several strategic initiatives, including Rs 110.79 crore for expanding and upgrading manufacturing facilities, Rs 18.02 crore for establishing a new research and development center, and Rs 14.3 crore for the repayment of outstanding borrowings. Additionally, working capital requirements will be met with Rs 33 crore, and Rs 35.64 crore will be allocated for repaying loans used for subsidiary investments.

Sai Parenterals operates as a diversified pharmaceutical formulations company, with business segments including Branded Generic Formulations and Contract Development and Manufacturing Organisation (CDMO) services. Its product portfolio covers various therapeutic areas such as cardiovascular, neuropsychiatry, and anti-diabetic treatments, offered in multiple dosage forms. In the first half of the fiscal year 2026, the company reported a consolidated net profit of Rs 7.76 crore on sales of Rs 86.92 crore, with the domestic market contributing 76.21% to its revenue.